Today, we announced that the FDA has lifted the clinical hold placed on the Phase 1 LUMINA trial of our investigational antisense oligonucleotide targeting calpain-2 for the potential treatment of ALS. We are working to open trial sites across North America and continue to anticipate early cohort data this year. Learn more:

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about each of the core values guiding #TeamAmylyx below.

As we enter a new year, we are ushering in a new era for treating diseases with high unmet needs. Our commitment to the communities we serve is more than just a promise to work with urgency; it’s a personal responsibility. Discover more at

Earlier this week, we announced the appointment of Dan Monahan as Chief Commercial Officer. Dan joined Amylyx in January 2024 and has over 20 years of commercial leadership experience in the biopharmaceutical industry. Learn more about Dan's appointment here:

Progressive supranuclear palsy (#PSP) is characterized by abnormal tau inclusions and is consequently considered a tauopathy. Multiple pathways have been implicated as contributors to the tau dysfunction and aggregation that drive neurodegeneration in PSP. Learn more below.

We’re looking forward to attending the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (@WCIRDC) and presenting the design of our Phase 3 LUCIDITY clinical trial for the treatment of post-bariatric hypoglycemia (#PBH). More details below. #WCIRDC24

#TeamAmylyx is excited to be in Montreal this weekend at @mndaassoc’s 35th Annual Symposium on ALS/MND (#alsmndsymp). More details on the poster we’re presenting below.

#Wolframsyndrome is a rare, monogenic neurodegenerative disease with no disease-modifying treatment options for the ~3,000 people in the U.S., and more around the world, who are living with this condition. Learn more about the mechanism of disease informing our scientific approach below.

Today, we announced the design of our Phase 3 LUCIDITY clinical trial for our investigational, first-in-class GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia. We plan to initiate LUCIDITY in the first quarter of 2025. Learn more:

Thank you to @BCHCEngineering for hosting our Co-CEOs, Joshua Cohen and Justin Klee, last week. It was an exciting opportunity for Josh and Justin to speak with the next generation of entrepreneurs.

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about each of the core values guiding #TeamAmylyx below.

Symptomatic post-bariatric hypoglycemia (#PBH) affects ~8% of people who have undergone bariatric surgery and occurs, on average, 1-3 years post-surgery. PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. Learn more about PBH below.

Our work at Amylyx means we often confront the difficult truths of diseases with high unmet needs, including those of children living in families with ALS. We recently watched LUKi & the Lights (linked below) together as a team and found it a compassionate and honest depiction of ALS. Our heartfelt thanks to Dr. Melinda S. Kavanaugh, President of Global Neuro YCare and recent Amylyx Beyond the Diagnosis guest speaker, for sharing this animated film with us and empowering us to further raise awareness. Watch LUKi and the Lights here:

We’re excited to return to the @alsone_official #ALSResearchSymposium, joining others in industry to discuss current research that’s underway around the world. More details on Amylyx’ presentation below.

We’re looking forward to attending the @ChildNeuroSoc (CNS) Annual Meeting next week in San Diego, where we’ll be sharing results from our HELIOS trial in #Wolframsyndrome. More details below. #CNSAM

We recently announced positive topline data from our open-label, Phase 2 HELIOS clinical trial in 12 adults with Wolfram syndrome. The study showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with our investigational therapy, the study’s primary efficacy endpoint, in contrast to the expected decrease in pancreatic function with disease progression. To learn more about these results, watch our webinar, which is available here:

Earlier this week, our CMO Camille Bedrosian, MD, joined the @LongwoodLeaders Boston CEO Meeting for a panel on innovation in clinical trials. We are on a mission to discover and develop innovative treatments, and we’re proud to have participated in this important discussion.

We recently partnered with the Margaret Fuller Neighborhood House (@MFNH71) to create snack kits that will help families in the Greater Boston area. Thank you to the Amylyx team members who participated in this community give-back activity and who contribute to our culture of caring each and every day.

We’re excited to attend the upcoming @LongwoodLeaders Boston CEO Meeting on Monday! Amylyx’ Chief Medical Officer, Camille Bedrosian, MD, will join top industry voices to discuss innovation in clinical trials and the future of healthcare innovation.

Progressive supranuclear palsy (#PSP) is characterized by abnormal tau inclusions and is consequently considered a tauopathy. Multiple pathways have been implicated as contributors to the tau dysfunction and aggregation that drive neurodegeneration in PSP. Learn more below.